Trial Profile
An Evaluation of Bone Mineral Density in HIV-1-infected Adult Subjects Switching From a Tenofovir-containing Antiretroviral Therapy Regimen to a Dolutegravir Plus Rilpivirine Regimen
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Dolutegravir/rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Registrational
- Sponsors ViiV Healthcare
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.
- 23 May 2018 Results assessing health outcoms by using data from three studies (SWORD-1, SWORD-2 and DEXA sub-study) presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 12 Dec 2017 Results assessing changes at Week 48 in BMD after switching from a three-drug regimen containing tenofovir disoproxil fumarate to the NRTI-sparing dolutegravir+rilpivirine regimen, were published in the AIDS.